Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis.
Michelle L TasLisa W DootjesMarta FioccoRonald R de KrijgerMiranda P DierselhuisNatasha K A Van EijkelenburgMartine van GrotelKathelijne C J M KraalAnnemarie M L PeekGodelieve A M TytgatMax M van NoeselPublished in: Cancers (2021)
This study is the first to confirm the results of the COG-ANBL0032 study in a cohort treated with a different induction regimen. Anti-GD2 immunotherapy prevents late events, most significantly in patients older than 18 months of age at diagnosis.